• Ensysce Biosciences completed enrollment in the final stage of its PF614-MPAR-102 clinical study evaluating MPAR overdose-protection technology.
• Results have been presented previously; new data from the final stage will be presented in the future.
• Published findings indicate the drug maintained intended therapeutic exposure under normal use while limiting additional opioid release under excessive dosing.
• Program remains positioned as a Breakthrough Therapy-designated, first-in-class opioid approach aimed at reducing oral overdose risk in pain treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608310830ACCESSWRNAPR_____1214652) on August 31, 2026, and is solely responsible for the information contained therein.